Table 4. Univariable and multivariable analyses of overall survival in patients with first- or second-line immunotherapy (n=129).
| Features | Univariable model | Multivariable model | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (>65 vs. ≤65 years) | 1.823 (0.973–3.419) | 0.06 | |||
| Sex (male vs. female) | 0.410 (0.212–0.792) | 0.008 | 0.410 (0.212–0.792) | 0.008 | |
| Pathological staging (IV vs. I or II or III) | 1.739 (0.927–3.261) | 0.09 | |||
| Pathological type (SCLC vs. NSCLC) | 0.944 (0.435–2.049) | 0.88 | |||
| Tobacco use history (yes vs. no) | 0.900 (0.484–1.675) | 0.74 | |||
| Alcohol use history (yes vs. no) | 0.548 (0.238–1.262) | 0.16 | |||
| RBC | 0.539 (0.361–0.976) | 0.04 | |||
| ALB | 0.978 (0.928–1.030) | 0.40 | |||
| BASO% | 0.870 (0.472–1.604) | 0.66 | |||
| EO% | 0.900 (0.744–1.089) | 0.28 | |||
HR, hazard ratio; CI, confidence interval; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; RBC, red blood cell; ALB, albumin; BASO%, percentage of basophil cell; EO%, percentage of acidophilic cell.